Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Viracta closes Series C; new partner Salubris participates

Executive Summary

Viracta Therapeutics Inc. closed its Series C round, led by a $10mm investment from new partner Shenzhen Salubris Pharmaceuticals Co. Ltd. Returning backers NantKwest, Latterell Venture Partners, and Forward Ventures also participated. Viracta is developing treatments for viral-related cancers, and concurrent with the Series C round, granted Salubris exclusive rights to develop and sell its lead candidate nanatinostat/valganciclovir in China for Epstein Barr virus-associated lymphomas, solid tumors, and for the prevention of EBV-associated post-transplant lymphoproliferative disorder. The project is currently in Phase Ib/II trials.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies